What Sanofi China does

Sanofi China is the local operating subsidiary of Sanofi S.A. (EPA:SAN), the Paris-headquartered global biopharmaceutical company, and has been present in the Chinese market since 1982. The subsidiary conducts research and development, manufacturing, and commercialization of innovative therapeutic products across immunology, oncology, cardiovascular disease, rare diseases, vaccines, and diabetes. Its footprint includes the Shanghai regional headquarters, a Beijing R&D center with 230+ staff covering regulatory affairs, development, and global operations, the Suzhou Global Research Institute focused on early-stage oncology and immuno-inflammation research, the Beijing insulin production base (Sanofi's largest in Asia-Pacific), and the Chengdu Innovation and Operations Center that opened in March 2026.

The company operates an AI-enabled R&D platform and digital commercial systems, applying predictive analytics to drug safety and using AI to accelerate compound development across therapeutic areas. The technology stack integrates immunoscience expertise with data platforms for drug discovery, clinical development, and omnichannel customer engagement in China. Product offerings span prescription drugs, vaccines (including pediatric, flu, RSV, and travel), and insulin pens manufactured domestically.

Commercially, Sanofi China runs a direct field sales model targeting hospitals and medical institutions, with district managers and medical information communication representatives organized by therapeutic area, alongside pharmacy distribution and government partnerships for national immunization programs. Revenue streams are diversified across pharmaceutical products, vaccines, and insulin/diabetes care, with pricing determined by government-negotiated reimbursement and prescription channels rather than disclosed enterprise contracts. The subsidiary has been ranked the #1 Top Employer in China for six consecutive years (2021-2026) and has been recognized by the World Economic Forum as a Skills Lighthouse institution.

Name

Sanofi China

Legal name

赛诺菲（中国）投资有限公司

Website

https://sanofi.cn

Company type

Public

Founded year

1982

Operating status

Operating

Headcount range

1–10 employees

Short description

Sanofi China is the Shanghai-incorporated subsidiary of Sanofi S.A., operating since 1982 in the research, development, manufacturing, and commercialization of innovative medicines and vaccines across immunology, oncology, cardiovascular, rare diseases, vaccines, and diabetes for the Chinese market.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA), Travel & Tropical Disease Vaccines (HLAIAEAE), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Pharmaceutical products
• Vaccine development
• Biopharmaceutical R&D
• Insulin manufacturing
• Immunology therapeutics

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical products: Revenue from prescription drugs across multiple therapeutic areas including immunology, cardiovascular, oncology, and rare diseases.
2. Vaccines: Revenue from vaccine products including pediatric vaccines, travel vaccines, and seasonal vaccines like flu and RSV prevention.
3. Insulin and diabetes care: Revenue from insulin products manufactured at the Beijing production base, serving the Asia-Pacific region.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Sanofi China researches, develops, manufactures, and markets innovative pharmaceutical products and vaccines in China, spanning therapeutic areas such as immunology, cardiovascular, oncology, rare diseases, and diabetes care. Core offerings include a vaccines portfolio (pediatric, flu, RSV, and travel vaccines), insulin injection pens manufactured in Beijing for the Asia-Pacific market, and specialty prescription drugs for immune-mediated, rare, and serious diseases. The company supports its portfolio with AI-powered R&D, an immunoscience platform, and a field sales force targeting hospitals, medical institutions, and government vaccination programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Vaccines portfolio (Sanofi Vaccines China) Sanofi's vaccines portfolio for the China market, covering pediatric, seasonal (flu), travel, and specialty vaccines, distributed via hospitals, pharmacies, and government public health programs.
• Insulin injection pens (Sanofi Beijing insulin production) Insulin injection pens and diabetes care products manufactured at Sanofi's Beijing production base, serving the Asia-Pacific region. The Beijing facility is Sanofi's largest insulin production center in the region.
• Prescription pharmaceuticals (Sanofi China specialty medicines) Sanofi's prescription pharmaceutical portfolio sold in China, covering immunology, cardiovascular, oncology, rare diseases, blood disorders, and neurological disorders for hospitals, physicians, and patients.
• Beyfortus (RSV vaccine for infants) Beyfortus is Sanofi's RSV (respiratory syncytial virus) prevention product for infants, positioned as a breakthrough in the pediatric vaccines portfolio.
• Aficamten (cardiac myosin inhibitor for hypertrophic cardiomyopathy) Aficamten is a cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy; in-licensed for the Greater China market through a partnership with Ji Xing.
• Plozasiran Sodium Injection (普乐司兰钠注射液) Plozasiran Sodium Injection is an investigational nucleic acid drug for cardiovascular/lipid diseases, licensed in to Sanofi for the Greater China market from a Viatris subsidiary.

Quantifiable outcome

• 40+ innovative drugs and vaccines brought to China since 1982, treating 70% of life-threatening serious diseases
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Partnerships

Four partnerships are on record, tiered major and minor.

• Viatris subsidiary (维亚臻)majorStrategic or Co-development Partner · 1 August 2025Sanofi obtained Greater China rights for Viatris subsidiary's investigational drug Pulsi Lanna sodium injection (普乐司兰钠注射液).
• Ji Xing (箕星)majorStrategic or Co-development Partner · 20 December 2024Sanofi and Ji Xing announced agreement for Aficamten in Greater China market. Ji Xing develops and commercializes cardiovascular innovative drugs in China, with Sanofi gaining rights for this therapeutic candidate in the Greater China region.
• French healthcare institutionsminorStrategic or Co-development Partner · 25 May 2024Dermatology and immunology care initiative celebrating China-France health cooperation for children, part of Sanofi's commitment to China-France healthcare exchange.
• Shanghai Soong Ching Ling Foundation (上海宋庆龄基金会)minorStrategic or Co-development Partner · 22 March 2024Sanofi partnered with Shanghai Soong Ching Ling Foundation to launch youth health awareness and education program, supporting adolescent health education initiatives.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Novartis China: Novartis China is a comparable multinational innovator pharma subsidiary with overlapping therapeutic areas in cardiovascular, immunology, and rare diseases. Both rely heavily on NRDL inclusion and hospital channel sales forces.
• Johnson & Johnson Innovative Medicine China: J&J Innovative Medicine China competes with Sanofi in immunology, oncology, and rare disease therapeutic areas. Both operate specialty sales models targeting hospital specialists and key opinion leaders.
• Eli Lilly China: Eli Lilly China is a comparable multinational pharmaceutical subsidiary with significant overlap in diabetes (insulin and beyond) and immunology therapeutic areas. Both compete directly in the insulin manufacturing space in China.
• Pfizer China: Pfizer operates a similar multinational pharmaceutical subsidiary in China with a comparable therapeutic focus spanning vaccines, oncology, rare diseases, and primary care. Both compete directly for hospital channel access, NRDL inclusion, and physician engagement.
• AstraZeneca China: AstraZeneca China is one of Sanofi's closest peers in cardiovascular, respiratory, and oncology in China, with similar reliance on NRDL inclusion and large field sales organizations. AstraZeneca is the largest multinational pharma player in China by revenue, setting competitive benchmarks.
• AbbVie China: AbbVie China competes with Sanofi in immunology (Humira biosimilar competition, Skyrizi/Rinvoq positioning) and oncology. Both rely on specialty pharmacy and hospital immunology channel access.
• Roche China: Roche China competes head-to-head with Sanofi in specialty pharmaceuticals, oncology, and immunology across hospital and pharmacy channels in China. Both share similar GTM models via field sales targeting hospitals and physicians.
• Merck & Co. (MSD) China: MSD China is a direct peer as a multinational pharmaceutical subsidiary with strong vaccine (HPV, pneumococcal) and oncology franchises. Both compete in hospital channel access and government vaccination program tenders.
• GSK China: GSK China is a direct peer in vaccines (including pediatric and travel) and specialty pharmaceuticals with a similar GTM motion targeting hospitals and government immunization programs. Both face comparable NRDL and VBP pricing dynamics.

Regional players

• Sinopharm Group: Sinopharm is a state-owned domestic Chinese pharmaceutical distributor and manufacturer that competes with Sanofi primarily in vaccine distribution, government immunization programs, and pharmaceutical wholesale channels in the China market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanofi China